Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

PLASMA 2 Trial: Examination of Once Daily (QD) Dosing of A-002 In Subjects With Stable Coronary Artery Disease (PLASMA 2)

3 januari 2008 uppdaterad av: Anthera Pharmaceuticals

Phospholipase Levels And Serological Markers of Atherosclerosis 2: An Examination of Once Daily (QD) Dosing of A-002 In Subjects With Stable Coronary Artery Disease

The study will be conducted at up to 25 U.S. centers and will be a double-blind randomized parallel group placebo controlled study among subjects with stable coronary artery disease (CAD). Subjects will be randomized to receive either placebo tablets or one of 2 orally active doses of A-002. The duration of study drug therapy will be 8 weeks.

Studieöversikt

Status

Avslutad

Betingelser

Intervention / Behandling

Detaljerad beskrivning

A-002 represents a novel therapy for the treatment of atherosclerosis and coronary artery disease (CAD). Through the inhibition of activity A-002 may provide multifunctional activity directed against key facets of the disease process, namely a) inflammation, b) atherogenic lipid profiles and c) the atherosclerotic process. Non-clinical and clinical data from recent studies have demonstrated the benefit of early and aggressive anti-inflammatory therapy to reduce cardiovascular risk. Recent clinical studies have provided a strong association between levels and cardiovascular event risk. The proposed Phase 2 clinical pharmacology study (Study No. AN-CVD-2222) will examine the effects of 2 different doses of A-002 compared with placebo, on enzyme levels and activity after 8 weeks of treatment. In addition, the effect of treatment on inflammatory markers of cardiovascular risk (C-reactive protein [CRP]), lipid levels and lipoprotein subclasses and other soluble biomarkers (e.g., ICAM-1, VCAM-1, TNF, MCP-1 etc) will also be assessed.

Studietyp

Interventionell

Inskrivning (Förväntat)

120

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

  • Förenta staterna
    • Alabama
      • Mobile, Alabama, Förenta staterna, 36608
        • Mobile Heart Specialists
    • Arizona
      • Scottsdale, Arizona, Förenta staterna, 85260
        • Sonoran Health Specialists
    • Florida
      • Hudson, Florida, Förenta staterna, 34667
        • Pasco Cardiology Center
      • Port Charlotte, Florida, Förenta staterna, 33952
        • Charlotte Cardiovascular Institute
      • Tampa, Florida, Förenta staterna, 33609
        • Florida Cardiovascular Research Institute
    • Georgia
      • Augusta, Georgia, Förenta staterna, 30901
        • Augusta Cardiology Clinic
    • Kentucky
      • Louisville, Kentucky, Förenta staterna, 40207
        • Louisville Cardiology Medical Group
    • Maine
      • Auburn, Maine, Förenta staterna, 04210
        • Maine Research Associates
    • New York
      • Binghamton, New York, Förenta staterna, 13901
        • United Medical Associates
      • Syracuse, New York, Förenta staterna, 13210
        • Cardiology PC
    • Texas
      • Austin, Texas, Förenta staterna, 78705
        • Austin Heart
    • Virginia
      • Norfolk, Virginia, Förenta staterna, 23507
        • Clinical Research Associates of Tidewater
    • Wisconsin
      • Madison, Wisconsin, Förenta staterna, 53715
        • Wisconsin Heart, SC

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

Subjects are eligible for inclusion if they meet the following inclusion criteria:

  1. Men and women ≥18 years of age
  2. Written informed consent from the subject
  3. Stable CAD
  4. Stable medical condition, will be compliant and able to comply with the requirements of the protocol

Exclusion Criteria:

Subjects must NOT meet any of the following exclusion criteria:

  1. Planned coronary artery bypass surgery (CABG)
  2. Acute or chronic heart failure as defined by the New York Heart Association (NYHA) classification as functional Class III or Class IV
  3. Hospitalization for acute coronary syndrome (ACS) if troponin >0.1 ng/mL in the preceding 6 weeks
  4. Hospitalization for ST-segment elevation acute myocardial infarction (STEMI) in the preceding 12 weeks
  5. Subjects with chronic inflammatory disease (e.g., rheumatoid arthritis), inflammatory bowel disease, recent (12 weeks) systemic or localized infection (the latter requiring clinical intervention), or major surgery
  6. hs-CRP ≥15 mg/L repeated on at least 2 occasions >24 hours apart due to non-cardiovascular systemic inflammatory conditions (e.g., rheumatoid disease)
  7. Subjects enrolled in another experimental (interventional) protocol within the past 30 days prior to Screening or prior experience with A-002.
  8. Subjects treated for cancer within the previous 5 years except for skin basal cell carcinoma or carcinoma in situ of the cervix, with measures other than a minor, complete surgical excision (e.g., chemotherapy), or radiation therapy
  9. Subjects who have received immunosuppressant therapy within 30 days prior to entry
  10. Subjects who have received anti-tumor necrosis factor (for example, infliximab) therapy within 6 months prior to entry
  11. The presence of severe liver disease with cirrhosis, recent active hepatitis, active chronic hepatitis, ALT or AST >3 x upper limit of normal, biliary obstruction with hyperbilirubinemia (total bilirubin >2 x upper limit of normal)
  12. Active cholecystitis, gall bladder symptoms, or potential hepato-biliary abnormalities
  13. The presence of moderate or severe renal impairment (CrCl <60 mL/min or creatinine >1.5 x upper limit of normal), nephrotic syndrome, or subjects undergoing dialysis
  14. Uncontrolled diabetes mellitus (known HbA1c >11% within the last 1 month prior to screening)
  15. Females who are nursing, pregnant, or intend to become pregnant during the time of the study, or subjects who have a positive serum pregnancy test at Visit 1 (if the subject is a female of child-bearing potential). Women of child-bearing potential must also use a reliable method of birth control during the study and for 1 month following completion of therapy. A reliable method for this study is defined as one of the following: oral or injectable contraceptives, intrauterine device (IUD), contraceptive implants, tubal ligation, hysterectomy, a double-barrier method (diaphragm with spermicidal foam or jelly, or a condom).
  16. Subjects who have a history of alcohol or drug abuse within 1 year of study entry
  17. Subject living too far from participating center or unable to return for follow-up visits
  18. Subjects who in the opinion of the Investigator are a poor medical or psychiatric risk for therapy with an investigational drug, are unreliable, or have an incomplete understanding of the study which may affect their ability to take drugs as prescribed or comply with instructions
  19. Known human immunodeficiency virus (HIV), Hepatitis B virus (HBV), or Hepatitis C Virus (HCV) infection
  20. Treatment with any systemic corticosteroid within the 30-day period prior to study entry or the use of inhaled steroids within the 14-day period prior to study entry

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Förebyggande
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Dubbel

Vad mäter studien?

Primära resultatmått

Resultatmått
The primary objective of this study is to determine the effect of once daily (QD) dosing of A-002 on sPLA2 levels and activity

Sekundära resultatmått

Resultatmått
Determine the effect of QD dosing of A-002 on sPLA2 levels and activity at each time point (Weeks 2, 4, and 8)
Compare the effect of QD dosing of A-002 on sPLA2 enzyme levels and markers of inflammation
Determine plasma drug concentrations with QD dosing

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Anthera Pharmaceuticals

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Allmänna publikationer

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart

1 september 2007

Avslutad studie

1 december 2007

Studieregistreringsdatum

Först inskickad

4 september 2007

Först inskickad som uppfyllde QC-kriterierna

5 september 2007

Första postat (Uppskatta)

6 september 2007

Uppdateringar av studier

Senaste uppdatering publicerad (Uppskatta)

7 januari 2008

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

3 januari 2008

Senast verifierad

1 januari 2008

Mer information

Termer relaterade till denna studie

Nyckelord

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • AN-CVD2222

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera